Hirschfield, Gideon M.

Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis

Trivedi, P. J., Muir, A. J., Levy, C., Bowlus, C. L., Manns, M. P., Lu, X., Crans, G., Chung, C., Subramanian, G. M., Myers, R. P., et al. (2021) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 55

X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

Asselta, R., Paraboschi, E. M., Gerussi, A., Cordell, H. J., Mells, G. F., Sandford, R. N., Jones, D. E., Nakamura, M., Ueno, K., Hitomi, Y., et al. (2021) · Gastroenterology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 55

Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps

van Erp, L. W., Cunningham, M., Narasimman, M., Ale Ali, H., Jhaveri, K., Drenth, J. P. H., Janssen, H. L. A., Levy, C., Hirschfield, G. M., Hansen, B. E., et al. (2020) · Liver International

Cholangiocarcinoma and Gallbladder Cancer StudiesLiver Diseases and Immunity

Cited by 46

The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis

Barron‐Millar, B., Ogle, L., Mells, G., Flack, S., Badrock, J., Sandford, R., Kirby, J., Palmer, J., Jopson, L., Brain, J., et al. (2021) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 45

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 39

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

Murillo Perez, C. F., Ioannou, S., Hassanally, I., Trivedi, P. J., Corpechot, C., van der Meer, A. J., Lammers, W. J., Battezzati, P. M., Lindor, K. D., Nevens, F., et al. (2023) · Liver International

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 39

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 38

Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody–positive versus antimitochondrial autoantibody–negative primary biliary cirrhosis

Jin, Q., Moritoki, Y., Lleo, A., Tsuneyama, K., Invernizzi, P., Moritoki, H., Kikuchi, K., Lian, Z.-X., Hirschfield, G. M., Ansari, A. A., et al. (2012) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 37

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Hirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., et al. (2026) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 34

Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom

Rice, S., Albani, V., Minos, D., Fattakhova, G., Mells, G. F., Carbone, M., Flack, S., Varvaropoulou, N., Badrock, J., Spicer, A., et al. (2021) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityHealth Systems, Economic Evaluations, Quality of Life

Cited by 32

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis

Martinez-Gili, L., Pechlivanis, A., McDonald, J. A. K., Begum, S., Badrock, J., Dyson, J. K., Jones, R., Hirschfield, G., Ryder, S. D., Sandford, R., et al. (2023) · Gut Microbes

Liver Diseases and ImmunityGut microbiota and health

Cited by 32

Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis

Dinani, A. M., Fischer, S. E., Mosko, J., Guindi, M., & Hirschfield, G. M. (2012) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 32

Renaming primary biliary cirrhosis—clarity or confusion?

Trivedi, P. J., & Hirschfield, G. M. (2015) · Nature Reviews Gastroenterology & Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 22

The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study

Jones, D. E. J., Wetten, A., Barron-Millar, B., Ogle, L., Mells, G., Flack, S., Sandford, R., Kirby, J., Palmer, J., Brotherston, S., et al. (2022) · eBioMedicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 22

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results

Levy, C., Trivedi, P. J., Kowdley, K. V., Gordon, S. C., Bowlus, C. L., Londoño, M. C., Hirschfield, G. M., Gulamhusein, A., Lawitz, E. J., Vierling, J. M., et al. (2026) · American Journal of Gastroenterology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 20

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

Harms, M. H., Hirschfield, G. M., Floreani, A., Mayo, M. J., Parés, A., Liberman, A., Malecha, E. S., Pencek, R., MacConell, L., & Hansen, B. E. (2021) · JHEP Reports

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 17

P1198 : Histological stage is relevant for risk-stratification in primary biliary cirrhosis

Carbone, M., Sharp, S. J., Heneghan, M. A., Neuberger, J. M., Hirschfield, G. M., Burroughs, A. K., Thorburn, D., Bathgate, A., Aldersley, M., Adgey, C., et al. (2015) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 15

P1152: a comparative study of pruritus in PBC cohorts from UK, USA and Italy

Hegade, V. S., Mells, G. F., Lammert, C., Juran, B., Lleo, A., Carbone, M., Lazaridis, K., Invernizzi, P., Kendrick, S., Sandford, R., et al. (2015) · Journal of Hepatology

Liver Diseases and ImmunityDermatology and Skin Diseases

Cited by 15

P1184 : Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis

Cheung, A. C., Lammers, W. J., Hirschfield, G. M., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., Pares, A., et al. (2015) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 12

964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)

Marschall, H.-U., Luketic, V., Lovgren-Sandblom, A., Benthin, L., Kowdley, K., Hirschfield, G., Mason, A., Lindor, K., Gordon, S., Vincent, C., et al. (2012) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 9

Overlap syndrome: A real syndrome?

Haldar, D., & Hirschfield, G. M. (2014) · Clinical Liver Disease

Liver Disease and TransplantationLiver Diseases and Immunity

Cited by 9

Making the most of new genetic risk factors – genetic and epigenetic fine mapping of causal autoimmune disease variants

Mells, G. F., & Hirschfield, G. M. (2015) · Clinics and Research in Hepatology and Gastroenterology

Genetic Associations and EpidemiologyBioinformatics and Genomic Networks

Cited by 8

The 6 C's of primary sclerosing cholangitis

Deeb, M., Karlsen, T. H., & Hirschfield, G. M. (2020) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 5